Re: Fouad Y, et al. The NAFLD‐MAFLD debate: Eminence versus evidence. Liver Int. 2020 Nov 21. doi: 10.1111/liv.14739

We read with interest the article published by Fouad et al regarding the re-naming of NAFLD to Metabolic (Dysfunction) Associated Fatty Liver Disease or (MAFLD) and a way to settle this debate through evidence (1). We agree with the authors that fueling this debate is not productive. That said there are some concepts that are worth mentioning. There is no question that the consensus of experts that proposed that the change in name is quite a significant advance in understanding this entity and establishes specific diagnostic criteria that allow a better definition of the population (2,3).